Abstract: A trailer merge function of a tow vehicle includes receiving sensor data from one or more tow vehicle first sensors of an environment that is rearward of a connected tow vehicle. The method includes determining whether pattern associated with the sensor data matches a predetermined pattern corresponding to sensor data in which a field of view of the one or more first sensors is at least partly blocked by a trailer connected to the tow vehicle. Responsive to determining that the trailer at least partly obstructs the field of view of the one or more first sensors, sending a signal for warning a driver of the tow vehicle of lesser functionality of a trailer merge function, or increasing a reliance of one or more other sensors mounted to the tow vehicle, different from the one or more first sensors, in performing the trailer merge function.

Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

Abstract: Phytosphingosine derivatives suitable as adjuvants in immune stimulation, pharmaceutical compositions comprising such compounds and the medical use of the compounds and/or compositions in therapeutic or prophylactic methods of immune stimulation in a subject, and for use in the treatment of a disease, for which stimulation of an immune response in a subject produces a therapeutic benefit. The phytosphingosine derivative may also be used as adjuvants in vaccinating a subject. The phytosphingosine derivative may also be used in stimulating antibody production, stimulating an immune response against infection, stimulating an immune response against a cancer, or preventing and/or treating septic shock. Methods for the manufacture of the derivatives comprising an Ugi-4-component reaction (Ugi-4CR) is also disclosed.

Abstract: According to examples, an apparatus may include a processor and a memory on which is stored instructions that when executed by the processor, cause the processor to determine that data stored in a memory device of a printer cartridge installed in a printing device is to be updated. The printing device may be in remote communication with the apparatus via a network connection. The instructions may also cause the processor to identify update data that is to be used to update the data stored in the memory device. The instructions may further cause the processor to communicate, via the network connection with the printing device, the identified update data to the printing device. The printing device may update the data stored in the memory device of the printer cartridge with the update data.

Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

Abstract: A panel is disclosed, including a first facesheet, a second face sheet, and a plurality of pultrusion-formed web structures. Each web structure has a middle support portion, a first end portion, and a second end portion. The first end portion of each web structure is attached to the first facesheet and the second end portion of each web structure is attached to the second facesheet. The middle support portion, first end portion, and second end portion of each web structure form a single monolithic structure.

Abstract: In a first aspect, the present invention relates to cyclic dinucleotide compounds, in particular, c-di AMP for use in a method of inducing or promoting an immune response in an individual wherein said individual is a neonate or infant. The compound according to the present invention is particularly useful for use in therapeutic or prophylactic vaccination. In a further aspect, pharmaceutical compositions comprising the compound according to the present invention as an adjuvant, a pharmaceutically active ingredient for use as defined herein, in particular, as an adjuvant in a vaccine for unborn children, neonates and infants are provided. Finally, the present invention relates to a kit comprising a compound according to the present invention as an adjuvant, an antigen comprising antigenic structure as active vaccination component, in particular, to the use of said kit in a use of preventing or treating a disease.

Abstract: A composite tank for a reusable launch vehicle comprises a composite wall, having a first coefficient of thermal expansion. The composite wall comprises a first end, a second end, a central axis, which passes through the first end and through the second end, and a cylindrical interior surface. The composite tank also comprises slosh baffles, formed from a second material, having a second coefficient of thermal expansion that is different from the first coefficient of thermal expansion. Each of the slosh baffles is attached to the cylindrical interior surface of the composite wall. Each of the slosh baffles is annular and is separated from the cylindrical interior surface of the composite wall by a radial gap, selected, in part, based on a difference between the first coefficient of thermal expansion and the second coefficient of thermal expansion. The radial gap is configured to change responsive to changes in temperature of the composite tank.

Abstract: A panel is disclosed, including a first facesheet, a second face sheet, and a plurality of pultrusion-formed web structures. Each web structure has a middle support portion, a first end portion, and a second end portion. The first end portion of each web structure is attached to the first facesheet and the second end portion of each web structure is attached to the second facesheet. The middle support portion, first end portion, and second end portion of each web structure form a single monolithic structure.

Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

Abstract: A panel is disclosed, including a first facesheet, a second face sheet, and a plurality of pultrusion-formed web structures. Each web structure has a middle support portion, a first end portion, and a second end portion. The first end portion of each web structure is attached to the first facesheet and the second end portion of each web structure is attached to the second facesheet. The middle support portion, first end portion, and second end portion of each web structure form a single monolithic structure.

Abstract: In a first aspect, the present invention relates to a method for determining the responsiveness of an individual to vaccination, like viral vaccination or for the determination of viral vaccine efficacy in an individual as well as a method for the stratification of the vaccination regimen, e.g. viral vaccination, in an individual based on determining the level or the amount of at least one of IL-8 or IL-18 in a sample; said sample is obtained from an individual at least once before or at least once after vaccination. The method allows to determine the vaccination regimen with the vaccine, in particular, a virus vaccine, like an influenza virus vaccine whereby when a low level of at least one of IL-8 and/or IL-18 is determined, said low level is indicative for a personalized vaccine strategy. In a further aspect, the use of at least one of IL-8 or IL-18 as a predictive marker for vaccine efficacy or immune protection by vaccination is provided.

Abstract: The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

Abstract: A method for assembling a composite wall assembly edge joint including laying up a first composite face sheet, laying up a first composite buildup pad having a first tapered section onto the first composite face sheet and positioning a composite flute core member, including a tapered first portion with a first inclined surface and a second inclined surface. First inclined surface is positioned onto the first tapered section of the first composite buildup pad and a second portion of the composite flute core member extends from the tapered first portion along first composite face sheet. The method also includes laying up a second composite buildup pad having a second tapered section with the second composite buildup pad spaced apart from the first composite buildup pad and having at least a portion of the second tapered section overlying the second inclined surface of the tapered first portion.

Abstract: A hybrid softening strip for controlling stresses in a joint at low temperatures includes a layer of sacrificial material that can be tailored to fit the softening strip in the joint after the softening strip has been bonded to a structure.

Abstract: A composite wall assembly edge joint including a first composite buildup pad having a first tapered section is secured to and extends along a first composite face sheet. A second composite buildup pad having a second tapered section is secured to and extends along a second composite face sheet, wherein the first and second composite buildup pads are positioned between spaced apart first and second composite face sheets. A composite flute core member includes a tapered first portion positioned between and secured to the first tapered section and to the second tapered section. A second portion of the composite flute core member extends in a direction away from the tapered first portion of the composite flute core member and is positioned between, extends along and is secured to the first and second composite face sheets.

Abstract: A composite wall assembly edge joint, includes a first composite buildup pad secured to a first composite face sheet with the first composite buildup pad having a first tapered section with a first inclined surface which extends in a first direction and having a second section which extends from the first tapered section with a second surface which extends in a second direction, different from the first direction, toward a first end of the first composite face sheet. The assembly further includes a composite flute core member, having a tapered first portion secured to the first tapered section; a second portion secured to the first composite face sheet; and a third portion which extends in the second direction, away from the tapered first portion, toward the first end of the first composite face sheet secured to the second section.

Abstract: A method for assembling a composite wall assembly edge joint including laying up a first composite face sheet, laying up a first composite buildup pad having a first tapered section onto the first composite face sheet and positioning a composite flute core member, including a tapered first portion with a first inclined surface and a second inclined surface. First inclined surface is positioned onto the first tapered section of the first composite buildup pad and a second portion of the composite flute core member extends from the tapered first portion along first composite face sheet. The method also includes laying up a second composite buildup pad having a second tapered section with the second composite buildup pad spaced apart from the first composite buildup pad and having at least a portion of the second tapered section overlying the second inclined surface of the tapered first portion.

Abstract: A composite wall assembly edge joint including a first composite buildup pad having a first tapered section is secured to and extends along a first composite face sheet. A second composite buildup pad having a second tapered section is secured to and extends along a second composite face sheet, wherein the first and second composite buildup pads are positioned between spaced apart first and second composite face sheets. A composite flute core member includes a tapered first portion positioned between and secured to the first tapered section and to the second tapered section. A second portion of the composite flute core member extends in a direction away from the tapered first portion of the composite flute core member and is positioned between, extends along and is secured to the first and second composite face sheets.

Abstract: A composite wall assembly edge joint, includes a first composite buildup pad secured to a first composite face sheet with the first composite buildup pad having a first tapered section with a first inclined surface which extends in a first direction and having a second section which extends from the first tapered section with a second surface which extends in a second direction, different from the first direction, toward a first end of the first composite face sheet. The assembly further includes a composite flute core member, having a tapered first portion secured to the first tapered section; a second portion secured to the first composite face sheet; and a third portion which extends in the second direction, away from the tapered first portion, toward the first end of the first composite face sheet secured to the second section.